Cooper Companies is a global medical device company with two segments: CooperVision (contact lenses, ~67% of revenue) and CooperSurgical (fertility and women's health, ~33% of revenue). CooperVision manufactures a broad range of soft contact lenses — daily, two-week, and monthly — in silicone hydrogel and traditional hydrogel materials, across spherical, toric, and multifocal prescriptions. Key product families include Biofinity (monthly), MyDay (premium daily silicone hydrogel), and MiSight, the only FDA-approved contact lens for slowing myopia progression in children. CooperVision sells through eye care practitioners, optical chains, and distributors globally, and generates roughly one-third of its revenue through private label supply agreements with retailers. The core business model is recurring: lenses are consumables, so a fitted wearer generates a steady stream of purchases. Revenue growth is driven by wearer counts, modality mix (daily lenses generate more revenue per patient than monthlies), lens type mix (torics and multifocals carry price premiums), and pricing. CooperSurgical sells fertility consumables, lab equipment, and genomic testing services to IVF clinics; Paragard, a hormone-free copper IUD sold exclusively in the U.S.; surgical devices for OB/GYNs; and cryostorage services for cord blood and gametes. CooperSurgical's fertility consumables and cryostorage revenues are recurring, tied to IVF cycle volumes. Cooper is also conducting a formal strategic review to evaluate whether separating CooperVision and CooperSurgical would unlock shareholder value.